ARTV - Artiva Biotherapeutics, Inc.

5.74
0   0%

Share volume: 140,014
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.19%

PREVIOUS CLOSE
CHG
CHG%
$5.74
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 35%
Dept financing 26%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.52%
1 Month
53.48%
3 Months
86.36%
6 Months
85.76%
1 Year
7.09%
2 Year
-52.17%
Key data
Stock price
$5.74
P/E Ratio 
0.00
DAY RANGE
$5.50 - $5.90
EPS 
-$24.63
52 WEEK RANGE
$1.47 - $7.36
52 WEEK CHANGE
$8.10
MARKET CAP 
70.102 M
YIELD 
N/A
SHARES OUTSTANDING 
24.545 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-22-2025
BETA 
1.11
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$168,012
AVERAGE 30 VOLUME 
$141,980
Company detail
CEO: Fred Aslan
Region: US
Website: www.artivabio.com
Employees: 0
IPO year: 2024
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our principal executive offices are located at 5505 Morehouse Drive, Suite 100, San Diego, California.

Recent news